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Introduction
It is said that RM replaces or regenerates human cells, tissue 
or organs using different cell types and strategies.1 Stem cells, 
as an important source of cells used in regenerative medicine 
(RM), have the ability to renew themselves for long periods 
and can be differentiated into various cell types.2,3
Gene therapy can modify embryonic/adult stem cells or 
induced somatic cells into pluripotent stem cells (iPSCs) 
to further use in RM. Personalized medicine is a novel 
field of medicine which refers to the employing of specific 
therapeutics procedure for an individual. This approach has 
been established based on genomic information and data. 
Nowadays personalized medicine covers many fields of 
healthcare such as RM.4,5 
Accordingly, RM and cell-based therapy uses individual 
cell-based products in order to develop personalized 
treatments and regeneration. Science the use of gene therapy 
and personalized medicine can affect the efficiency of the 
regeneration strategies, it is suggested to apply genomic data 
of an individual in RM as personalized regenerative medicine 
or PRM.
In this article, different strategies such as cell therapy, gene 
therapy, RNA based therapy etc used in bone regeneration 
according to the use in bone PRM is presented.
Personalized Bone Regeneration
Personalized RM has 2 concerns. One concern which is 
related to construct or defect characteristics, is to produce 
or regenerate tissues or organs with appropriate sizes or 
dimensions, mechanical properties and etc tailored to the 
patient.6 Another concern which is related to applied strategy 
is the use of appropriate regeneration techniques tailored to 
the patient’s genetics in order to achieve best results. 
In order to appropriately design a construct, the scaffolds 
should consider the personalized functional requirements 
such as the external shape and size of the defect, porosity, and 
stiffness in order to avoid stress shielding and to stimulate the 
growth of the new tissue. For this purpose, three-dimensional 
bioprinters and different methods of providing three-
dimensional scaffolds adapted to the patient’s lesion were used. 
In order to investigate and select patient-centered strategies 
for bone regeneration, it is necessary for the patient to be 
genetically examined and gene expression profile, especially 
in the natural bone tissue must be assayed. For example in 
Gene-Enhanced Personalized Regenerative Medicine for 
Bone
Firoozeh Alavian1, Akram Alizadeh2,  Sorayya Ghasemi3* 
1Department of Biology, School of Basic Sciences, Farhangian University, Tehran, Iran
2Department of Tissue Engineering and Applied Cell Sciences, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, 
Iran
3Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, 
Iran
Corresponding Author: Sorayya Ghasemi, PhD of Medical Genetics, Assistant Professor, Cellular and Molecular Research Center, 
Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran. Tel: +98-38-33331471, Fax: +98-383-
3330709, Email: sorayya.ghasemi@gmail.com
Copyright © 2019 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is 
properly cited.
Abstract
Regenerative medicine (RM) is a developing multidisciplinary science that uses different principles and methods of other fields or sciences for 
tissue regeneration, repair or replacement. Gene therapy refers to transferring genes or gene expression regulator factors for the desired purposes. In 
some cases, gene therapy plays an important role in regenerative medicine by modulating stem cells from different sources. Genetic heterogeneity 
of individuals can affect the results of gene therapy or other therapies in RM. This is why personal genomics should be considered in RM and is 
called personalized regenerative medicine (PRM). The purpose of PRM is to employ strategies and methods tailored to the individual’s genetics in 
order to efficiently reconstruct or substitute various parts of the body. In this study, the strategies and recent advances in bone regeneration such as 
gene therapy, epigenetic-based therapies,  RNA-based therapy and CRISPR/Cas9 system with an attitude to personalized medicine are introduced.
Keywords: Bone, Regenerative Medicine, Gene Therapy, Epigenetic, Personalized Medicine
Citation: Alavian F, Ghasemi S, Alizadeh A. Gene-enhanced personalized regenerative medicine for bone. J Appl Biotechnol Rep. 2019;6(1):1-5. 
doi:10.29252/JABR.06.01.01.
Received July 30, 2018; Accepted October 19, 2018; Online Published March 15, 2019
J Appl Biotechnol Rep. 2019 Mar;6(1):1-5
Review Article
10.29252/JABR.06.01.01doi
Applied Biotechnology
Reports
Journal of 
Alavian et al
J Appl Biotechnol Rep, Volume 6, Issue 1, 2019                                         http://www.biotechrep.ir2
one patient, the use of gene therapy for a special growth factor 
may be more effective than other growth factors due to its 
genetics. In one patient, using siRNA against corticosteroids 
receptors may be more effective than other strategies.6
Personalized Cell Therapy in Bone Regeneration
There are some limitations in the clinical utility of stem 
cells. For example the immune rejection of heterologous 
stem cells, limit their applications.7 Also, the low quantity 
of reachable autologous cells requires in vitro expansion in 
xeno-derived media and may result in genomic alterations 
and unwanted cell differentiation and functions. This is why 
some appropriate tests should be performed for analyzing 
cells before transplantation. Additionally, the safety and 
regulation of these procedures must be performed before 
clinical trials.8-10 Banking and the use of human cord blood 
stem cells or iPSCs) in order to achieve personalized cell 
source will be an approach in personalized cell therapy in 
bone regeneration.11
Gene Therapy in Bone Regeneration
Bone regeneration can be enhanced through the delivery of 
genes or other regulators of genes that stimulate osteogenesis 
and angiogenesis.12 Gene therapy is transferring DNA or 
RNA into cells for some proposes.13 In vivo, ex vivo and in 
situ approaches are the most popular local gene therapy in 
RM. The in vivo approach is simple, fast, and less expensive 
but the ex vivo gene therapy is safer and more helpful; because 
genetic manipulations get done outside the body. In this 
method, the progenitor cells can be used as a primer place for 
bone development. Both methods are presently used for bone 
regeneration.14 Viral and non-viral vectors can be used in 
RM.14,15 Viral and non-viral deliveries have some advantages 
and disadvantages. Ultimately, clinical trial for gene therapy 
in bone regeneration is essential for the follow-up study of 
side effects.13
Genes and Factors in Bone Gene Therapy 
In general, genes or factors that are used in bone regeneration 
can be divided into the following. The delivery of growth 
factor genes and the expression of these genes is the original 
item for modifying the bone matrix during bone curing for 
regeneration purposes.16 The GF regulate vascularization and 
induce proliferation and differentiation of osteoprogenitors 
cells and neighboring tissues in the periodontal and gingival 
structures. Hence, they can be valuable for improving the 
repairing processes and to stimulate bone regeneration. 
Transforming growth factor-b1 (TGFb1) is a growth factor 
that has an essential role in MSC stimulate to osteoblast 
precursors and chondrocyte proliferation. Also, TGFb1 has 
some functions in some extracellular bone matrix protein 
such as collagen, osteopontin, and alkaline phosphatase. On 
the other hand, biomaterials were advancely industrialized 
to combine GFs for synergistic effects on bone regeneration 
16. Finally, vascular endothelial growth factor (VEGF) is an 
important GF in bone formation and angiogenesis.17,18. The 
GF transcription factors, such as Runx2, Sox9, and Osterix 
are also necessary for osteoblastogenesis and regulators for 
osteogenesis of chondrocytes and osteoblasts and have been 
used in gene therapy for bone regeneration (Figure 1).19 
Epigenetic Therapy in Bone Regeneration
Epigenetic modifications lead to functional relevant 
alterations in the genome without any changes in the 
nucleotide sequence.21 Epigenetic mechanisms play 
essential roles in stem cell maintenance, differentiation and 
expression pattern during bone regeneration processes.22 In 
osteogenic differentiation of stem cells, DNA methylation, 
histone modifications, and microRNAs (miRs) regulation 
are involved in bone regeneration.23 For example, CpG 
methylation of the osteocalcin promoter considerably 
decreases during in vitro osteoblast differentiation of MSCs. 
In addition, hypermethylation of the LIN28 promoter reduces 
LIN28 expression during osteoblast differentiation. It has 
Figure 1. Some of the Factors and Genes Are Shown in Osteogenesis.20
                                               Personalized Bone Regeneration 
http://www.biotechrep.ir                                      J Appl Biotechnol Rep, Volume 6, Issue 1, 2019 3
been demonstrated that the activation of CDK1 promotes 
osteogenic differentiation of MSCs through phosphorylation 
of EZH2, the catalytic subunit of PRC2, that in turn catalyzes 
the methylation of histone H3 on lysine 27 (H3K27).24 
However, epigenetic mechanisms are not limited to the 
following.
MiRs in Bone Regeneration
The MiRs acts as the main regulators of bone formation, 
regeneration, and degeneration.25 The delivery of miRs is 
the most common epigenetics control that was used in bone 
regeneration. They regulate expression of many genes in 
various vital processes; including growth and differentiation. 
Also, MiRs play an essential role in any step of bone formation. 
MiRs regulate expression of genes by targeting mRNAs.26 
up-regulate or down-regulate occur in miRs expression 
throughout the development and differentiation process 
for therapeutic special effects.27 Ex vivo manipulation of the 
miRs levels is an important approach in the differentiation of 
various stem cells in RM.28 The use of miR levels could be 
an attractive approach for bone regeneration.29 MiRs that 
induced osteogenic had several fundamental functions in 
the stimulation of bone formation at different stages such 
as growth and development. Also, miRs contribute to the 
endochondral ossification process.30 So, particular miRs have 
essential roles in numerous pathways for promoting osteoblast 
differentiation.31 MiRs regulate osteogenic, adipogenic, and 
chondrogenic differentiation. There have been a number 
of the significant role of miRs in osteoblast proliferation 
and differentiation. For example, in positive osteogenesis, 
miRs can target Runx2 co-repressors in MSCs. This is while 
during negative osteogenesis, Runx2 or its co-activators can 
be targeted by miRs.32 For example, miR-29 is one type of 
miRs which its role in bone formation has been determined. 
Actually, miR-29 can stimulate osteogenic differentiation by 
targeting negative regulators on the related signaling pathway. 
It has also been shown that miR-34c with other signaling 
pathway are involved in osteogenic differentiation in mice.16 
Studies have shown that miRNA-26a can promote bone 
regeneration through the positive regulation osteogenesis.33
RNA-Based Therapy
Coding RNAs (mRNAs) code proteins in translation inside 
ribosome. Non-coding RNA are rRNA, tRNA, snRNA 
and other regulatory RNAs like short interference RNA 
(siRNA), microRNA (miRNA), short hairpin RNA (shRNA), 
Piwi-interacting RNA (piRNA) and Long noncoding RNA 
(lncRNA). Regulatory RNAs play a critical role in gene 
expression control in post-transcriptional, genomic and 
epigenomic levels.34-36 the RNA-based therapeutics such as the 
use of siRNAs, miRNAs, antisense oligonucleotides, aptamers, 
synthetic mRNAs and clustered regularly interspaced short 
palindromic repeats (CRISPR). CRISPR-associated protein-9 
(Cas9) nuclease are a relatively new class of treatment and 
prophylactic for a number of chronic and rare diseases.36-39 
It is also considered as a new method for tissue repair and 
regeneration (Advances in the delivery of RNA therapeutics: 
from concept to clinical reality, overcoming cellular barriers 
for RNA therapeutics, and RNA therapeutics for tissue 
engineering). RNA therapy because of its cytoplasmic function 
and degradation reduce the risk and have some advantages.40,41 
In the context of tissue engineering and RM, the probable 
turnover of the exogenous RNA is a further advantage.42 As 
conventional RNAs have strong immunogenicity and low 
stability, chemical modifications are needed to facilitate.25,43
CRISPR/Cas9 System 
The CRISPR/CRISPR-Cas9 pathway is revolutionizing 
biological research.44,45 Modifications to this primitive 
prokaryotic immune system now enable scientists to 
efficiently edit DNA or modulate gene expression in living 
eukaryotic cells and organisms.46,47 Thus, many laboratories 
can now perform important experiments that were previously 
considered as scientifically risky or too costly. 
Delivery Approachs for Gene Enhanced Regeneration
Sustainable local delivery, regulated gene expression, 
safety and failed clinical trial, are subjects which should be 
considered in gene therapy for RM.48,49 Viral transduction of 
target cells is a possible approach for regenerative applications. 
As mentioned, gene therapy by delivery through viral and 
non-viral vectors, lipid-based delivery systems and polymer-
based delivery systems are general approaches for RM.50 For 
gene and often for miRs delivery, systemic or local delivery 
systems could be used.51 Transfection for primary stem 
cells is more difficult than non-stem cell lines.52 Thus more 
efficient systems for miRs delivery are required for RM. Some 
regeneration methods are a prolonged process. Depending 
on the expression levels of the targets, miRs replacement or 
inhibition therapy that up-regulates miRs expression and 
down-regulates targets of miRs expression can be done.53 
Several viral and non-viral vectors with high transfection 
efficiency, excellent biocompatibility, and high-level targeting 
efficiencies have been developed.51
Viral Delivery Systems
Gene transfer mediated by viral vectors represents the 
most common approach in gene therapy studies.54 The 
different types of viral vectors whether integrated or non-
integrated form scan used for RM.55 The integrated viruses 
are important because they are stable and their expressions 
are continual. Under different conditions, such as bone 
regeneration, transient transgene expression is useful. For 
this aim, recombinant adenoviral vectors can be the most 
attractive. Also adenoviral vectors have the highest level of 
transgene efficiency. So, the use of adenovirus vectors in bone 
regeneration is common. Retroviral vectors have been also 
used in a small amount.14
Non-viral Delivery Systems
 Delivery of naked DNA/plasmids contains direct injection, 
liposome, particle or polymer mediated transfection, 
electroporation, etc. On the other hand, the use of non-viral 
delivery systems is limited by their efficiency of transfer 
and the level of transgene expression. Lipid or polymer-
based delivery systems can be used in the various opinion 
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of stem cell differentiation. Non-viral transmission systems 
are not appropriate for clinical applications in some cases. 
For some purposes such as a systemic anti-miR delivery was 
recommended nanoparticles and liposomes for delivery.56,57
Scaffold-Based Delivery Systems 
The scaffold-based delivery systems were planned to be a 
successful, stable, low cytotoxicity and efficient non-viral 
delivery system.58 Scaffold-mediated delivery via encapsulating 
the genes or miRs in or onto the tissue engineering scaffold 
can be used for more controlled and localized transfection in 
RM applications. The findings show some of the mechanisms 
of miRs regulation by biomaterials and their development. 
These delivery systems would have probable curative values 
in bone regeneration.59 Localized and efficient gene transfer 
can be promoted by exploiting the interaction between the 
vector or miRs and biomaterial.60 Different materials can be 
designed in order to use as gene delivery systems for bones. 
Biodegradable natural or synthetic materials or polymers 
with the potential of attachment and carrying vectors or 
other nucleic acids and analogs can be used. These systems 
in addition to carrying and delivering the desired construct 
can be effective in bone regeneration by itself.61 For example, 
chitosan-based hydrogel have been used in bone regeneration 
as gene delivery systems to transfer the BMP2 gene.62 
Conclusions
Personalized medicine is an important feature in RM. Since 
bone formation and regeneration processes take place using 
the cells and the co-expression of many molecules, including 
GFs, specific transcription factors, and morphogenic bone 
proteins, the understanding of which of the genes, factors or 
epigenetic modifications can lead to more success in a patient 
requires a related genomic analysis of the patient. Application 
of personalized bone regeneration approaches can greatly 
alter the outcomes in the near future.
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